These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29244162)

  • 21. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
    Pham PA; Dressler C; Eisert L; Nast A; Werner RN
    Rheumatol Int; 2019 Apr; 39(4):605-618. PubMed ID: 30684041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
    Mease PJ; Gottlieb AB; Berman A; Drescher E; Xing J; Wong R; Banerjee S
    Arthritis Rheumatol; 2016 Sep; 68(9):2163-73. PubMed ID: 27059799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
    Naik GS; Ming WK; Magodoro IM; Akinwunmi B; Dar S; Poulsen HE; Kristensen LE; Ellervik C
    Dermatology; 2017; 233(5):366-377. PubMed ID: 29258093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Dahal K; Sharma S
    Rheumatol Int; 2016 Aug; 36(8):1065-75. PubMed ID: 27105880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
    McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
    RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of IL-17 inhibitors for patients with psoriatic arthritis: a systematic review and meta-analysis.
    Gao Q; Zhao YX; Wang XJ; Shi J; Wang HM
    Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2958-2970. PubMed ID: 33877659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
    Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
    Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
    Mease PJ; McInnes IB; Tam LS; Eaton K; Peterson S; Schubert A; Chakravarty SD; Parackal A; Karyekar CS; Nair S; Boehncke WH; Ritchlin C
    Rheumatology (Oxford); 2021 May; 60(5):2109-2121. PubMed ID: 33844022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis.
    Eder L; Mylvaganam S; Pardo Pardo J; Petkovic J; Strand V; Mease P; Colaco K
    Lancet Rheumatol; 2023 Dec; 5(12):e716-e727. PubMed ID: 38251562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    McInnes IB; Mease PJ; Kirkham B; Kavanaugh A; Ritchlin CT; Rahman P; van der Heijde D; Landewé R; Conaghan PG; Gottlieb AB; Richards H; Pricop L; Ligozio G; Patekar M; Mpofu S;
    Lancet; 2015 Sep; 386(9999):1137-46. PubMed ID: 26135703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.
    Xu Y; Li Y; Dong M; Gao Z; Chen X; Liu H; Shen M
    Rheumatology (Oxford); 2020 Dec; 59(12):3657-3665. PubMed ID: 33038239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.
    Kavanaugh A; Ritchlin C; Rahman P; Puig L; Gottlieb AB; Li S; Wang Y; Noonan L; Brodmerkel C; Song M; Mendelsohn AM; McInnes IB;
    Ann Rheum Dis; 2014 Jun; 73(6):1000-6. PubMed ID: 24553909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt.
    Fiechter RH; de Jong HM; van Mens LJJ; Fluri IA; Tas SW; Baeten DLP; Yeremenko NG; van de Sande MGH
    Front Immunol; 2021; 12():611656. PubMed ID: 33746955
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.